Form 4: Beam Therapeutics Chief Legal Officer Receives 27,500 Restricted Stock Units
SEC Form 4 Filing
Christine Bellon, Chief Legal Officer of Beam Therapeutics, acquired 27,500 shares of common stock through restricted stock units on March 31, 2024.
Summary
- Christine Bellon, the Chief Legal Officer of Beam Therapeutics Inc., received 27,500 restricted stock units (RSUs) on March 31, 2024.
- These RSUs were granted under the company's 2019 Equity Incentive Plan.
- Each RSU represents the right to receive one share of Beam Therapeutics' common stock.
- The RSUs vest in four equal installments annually, contingent upon Bellon's continued service with the company.
Sentiment
Score: 7
Explanation: The document reflects a standard executive compensation practice, indicating stability and alignment of interests. The sentiment is neutral to positive.
Positives
- The grant of RSUs aligns the Chief Legal Officer's interests with those of the shareholders, incentivizing her to contribute to the company's long-term success.
- The vesting schedule encourages continued service and commitment to Beam Therapeutics.
Future Outlook
The vesting of the RSUs is contingent upon the Reporting Person's continued service with BEAM through each vesting date.
Industry Context
Grants of restricted stock units are a common form of executive compensation in the biotechnology industry, used to attract and retain talent and align their interests with those of shareholders.
Comparison to Industry Standards
- Equity compensation practices vary across the biotechnology industry, but RSU grants are a standard component of executive pay packages.
- Companies like CRISPR Therapeutics and Editas Medicine also utilize equity grants to incentivize their leadership teams.
- The size of the grant is likely benchmarked against peer companies of similar market capitalization and stage of development.
Stakeholder Impact
- Shareholders may view the RSU grant positively as it aligns management's interests with long-term company performance.
- Employees may see the grant as a sign of the company's commitment to its leadership team.
Key Dates
| Date | Description |
|---|---|
| 03/31/2024 | Date of transaction: Grant of 27,500 restricted stock units. |
| 04/02/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.